Johnson & Johnson (JNJ) 119.61 $JNJ Lanier Law
Post# of 273246
Posted On: 09/07/2016 11:03:09 PM
Johnson & Johnson (JNJ) 119.61 $JNJ
Lanier Law Firm Attorneys Earn Spots on 2016 Texas Super Lawyers List
PR Newswire - Wed Sep 07, 10:00AM CDT
The Lanier Law Firm in Houston is home to four attorneys who have earned spots on the 2016 Texas Super Lawyers list for their work in a variety of cases involving everything from maritime law to class actions to appellate work.
JNJ: 119.61 (-0.14)
Johnson & Johnson Partners with Global Citizen to Improve the Trajectory of Human Health Around the World
PR Newswire - Wed Sep 07, 9:25AM CDT
Johnson & Johnson is partnering with social action platform Global Citizen to help give every man, woman and child around the globe the opportunity for a healthier future. The partnership aims to create large-scale change for health systems through integrated solutions to help solve the world's most pressing public health challenges.
JNJ: 119.61 (-0.14)
Post Earnings Coverage as Cooper Cos Earnings Grows 97 Percent
ACCESSWIRE - Wed Sep 07, 8:16AM CDT
LONDON, UK / ACCESSWIRE / September 7, 2016 / Active Wall St. announces its post-earnings coverage on The Cooper Companies Inc. (NYSE: COO). The company released its financial results for the fiscal third quarter 2016 (Q3 FY16) on September 1, 2016. The Contact-lens company updated its financial guidance after stellar earnings results. Register with us now for your free membership at: http://www.activewallst.com/register/.
JNJ: 119.61 (-0.14), VRX: 30.27 (+0.80), COO: 188.56 (+0.26), NVS: 80.36 (+0.21), VRX.TO: 39.05 (+1.19)
AlterG® Announces Appointment of New CEO
PR Newswire - Wed Sep 07, 5:00AM CDT
AlterG, leader in medical and sports technology and emerging in the health and wellness space, today announced the appointment of Mr. Sanjay Gupta as CEO. Mr. Gupta comes to AlterG from healthcare powerhouse Johnson & Johnson, where he held both domestic and international positions with a focused emphasis of serving healthcare professionals and consumers with unique solutions for their unmet needs to create differentiated value related to wellness and disease management.
JNJ: 119.61 (-0.14)
Water Street Appoints Nicklaus Daley to Vice President
PR Newswire - Tue Sep 06, 11:32AM CDT
Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry, announced today that it has appointed Nicklaus Daley to vice president. Mr. Daley augments Water Street's team of senior investment professionals and former executives of health care corporations including Baxter International Inc., CVS Caremark Corporation, Johnson & Johnson and McKesson Corporation.
JNJ: 119.61 (-0.14), BAX: 45.90 (-0.05), CVS: 93.61 (+0.25)
NOVADAQ Announces Appointment of Karen A. Licitra to its Board of Directors
GlobeNewswire - Tue Sep 06, 7:00AM CDT
NOVADAQ Technologies Inc. ("NOVADAQ" or the "Company"
(NASDAQ:NVDQ) (TSX:NDQ), the leading developer and provider of clinically relevant fluorescence imaging solutions for use in surgical and diagnostic procedures, announced today that Karen A. Licitra will be joining the Company's Board of Directors.
JNJ: 119.61 (-0.14), NDQ.TO: 16.16 (-0.11), NVDQ: 12.38 (-0.20)
MP Objects Raises $10M Growth Equity From Updata Partners
PR Newswire - Tue Sep 06, 2:30AM CDT
MP Objects BV ("MPO" , the leading provider of cloud-based Customer Chain Control Software-as-a-Service ("SaaS" , today announced it has raised its first round of outside capital in a $10 million growth equity investment from Updata Partners. MPO's cloud-based SaaS allows its users, including international logistics leaders and blue chip companies such as CEVA, DSV, eBay, Geodis, IBM, Johnson & Johnson, Patagonia and Unilever, to manage and optimize individual customer orders through today's increasingly complex and global supply chains. MPO has experienced very strong revenue growth in recent years, and it will use the new investment to expand into the United States and scale its marketing and sales.
JNJ: 119.61 (-0.14), IBM: 161.64 (+1.29)
Johnson & Johnson (JNJ) Approaches New Downside Target of $118.71
Comtex SmarTrend(R) - Thu Sep 01, 9:12AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) have bearishly opened below the pivot of $119.32 today and have reached the first support level of $119.03. Investors may be interested in a cross of the next downside pivot targets of $118.71 and $118.10.
JNJ: 119.61 (-0.14)
Blog Coverage FDA Approves Novartis Erelzi as Biosimilar to Amgen's Enbrel
ACCESSWIRE - Thu Sep 01, 8:15AM CDT
LONDON, UK / ACCESSWIRE / September 1, 2016 / Active Wall St. blog coverage looks at the headline from Novartis AG (NYSE: NVS). On August 30, 2016, the US Food and Drug Administration (FDA) approved Novartis AG's drug Erelzi which is a biosimilar to Amgen Inc.'s (NASDAQ: AMGN) Enbrel. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
JNJ: 119.61 (-0.14), PFE: 34.84 (+0.07), AMGN: 170.63 (-0.21), NVS: 80.36 (+0.21)
GTx Appoints Dr. Garry Neil to Board of Directors
BusinessWire - Thu Sep 01, 6:00AM CDT
GTx, Inc. (Nasdaq: GTXI) today announced that Garry A. Neil, M.D., Chief Scientific Officer, Medgenics, Inc., has been appointed to the GTx, Inc. Board of Directors. Dr. Neil brings significant medical and drug development leadership to the GTx Board of Directors and a proven track record of turning new science into breakthrough commercial products. Dr. Neil will serve on both the Nominating & Governance and Scientific and Development Committees.
GTXI: 0.63 (+0.01), JNJ: 119.61 (-0.14), MDGN: 5.39 (-0.09)
Bendheim Appoints Eric Van de Bovenkamp New Global Sales Manager
PRWeb - Thu Sep 01, 2:36AM CDT
Bendheim, one of the foremost specialty glass companies in the United States, is pleased to welcome Eric Van de Bovenkamp as Global Sales Manager of its Architectural Glass division. Eric will be responsible for supporting and growing the company's extensive sales network throughout North America and overseas.
JNJ: 119.61 (-0.14)
Johnson & Johnson to Participate in 2016 Morgan Stanley Global Health Care Conference
PR Newswire - Wed Aug 31, 9:05AM CDT
Johnson & Johnson (NYSE: JNJ) will participate in the 2016 Morgan Stanley Global Health Care Conference on Wednesday, Sept. 14, at The Grand Hyatt Hotel in New York. Alex Gorsky, Chairman and Chief Executive Officer and Dominic Caruso, Executive Vice President, Chief Financial Officer will represent the Company in a session scheduled at 9:55 a.m. (Eastern Time).
JNJ: 119.61 (-0.14), MS: 31.69 (-0.06)
Multiple Myeloma Market 2030 Forecasts in 2016 Research Report
PR Newswire Europe - Wed Aug 31, 1:01AM CDT
PUNE, Maharashtra, August 31, 2016 /PRNewswire/ --
JNJ: 119.61 (-0.14)
Novartis wins US OK for biosimilar version of Amgen's Enbrel
By LINDA A. JOHNSON and MATTHEW PERRONE - AP - Tue Aug 30, 5:29PM CDT
U.S. regulators on Tuesday approved the first lower-cost version of Enbrel, a blockbuster anti-inflammatory drug from Amgen that is among the top-selling drugs in the world.
JNJ: 119.61 (-0.14), PFE: 34.84 (+0.07), AMGN: 170.63 (-0.21)
Global Contact Lens Market to Rise to 2,135.0 mn Units by 2024; Rising Prevalence of Ophthalmic Disorders and Rising Popularity as Fashion Accessory Boost Global Sales of Contact Lenses - TMR
PR Newswire - Tue Aug 30, 7:30AM CDT
Transparency Market Research estimates that the global contact lens market will expand at a healthy 7.6% CAGR over the period between 2016 and 2024. Expanding at this pace, the market, which had a valuation of US$9.74 bn in 2015 in terms of revenue, is projected to rise to US$18.70 bn by 2024. In terms of volume, the market is expected to rise to 2,135.0 mn units by 2024.
JNJ: 119.61 (-0.14)
Pol Polyprotein Pipeline Review, H1 2016 Featuring GeoVax Labs, Inovio Pharmaceuticals, & Johnson & Johnson - Research and Markets
BusinessWire - Mon Aug 29, 12:13PM CDT
Research and Markets has announced the addition of the "Pol Polyprotein - Pipeline Review, H1 2016" report to their offering.
JNJ: 119.61 (-0.14), INO: 9.05 (+0.05)
EPGL Wins Allowance on First Patent
PR Newswire - Mon Aug 29, 8:00AM CDT
EP Global Communications, Inc. (Public OTC: EPGL) announces today that it has been notified of an allowance from the United States Patent & Trademark Office on its first patent, US 14/668,957 "System for Contact Lens Wireless Communication." With this allowance, EPGL now has several patents pending in the new field of "smart contact lenses" and "augmented vision" technology.
JNJ: 119.61 (-0.14)
Dow 30 Stock Roundup: Pfizer's Big Buy, Boeing's Big Win
Swarup Gupta - Zacks Investment Research - Fri Aug 26, 8:24AM CDT
The Dow suffered losses over the week, weighed down by a number of factors.
MDVN: 80.97 (+0.13), JNJ: 119.61 (-0.14), GE: 31.06 (+0.01), GS: 169.67 (+0.34), PFE: 34.84 (+0.07), AZN: 33.18 (+0.09), MYL: 40.31 (-0.09), BWXT: 39.06 (-0.16), BA: 132.64 (-0.35), VZ: 53.71 (+0.20), MS: 31.69 (-0.06)
Johnson & Johnson to Participate in the 2016 Wells Fargo 11th Annual Healthcare Conference
PR Newswire - Thu Aug 25, 9:00AM CDT
Johnson & Johnson (NYSE: JNJ) will participate in the 2016 Wells Fargo 11th Annual Healthcare Conference on Thursday, Sept. 8, at The Westin Boston Waterfront in Boston, MA. Dominic Caruso, Executive Vice President, Chief Financial Officer will represent the Company in a session scheduled at 10:30 a.m. (Eastern Time).
JNJ: 119.61 (-0.14), WFC: 49.77 (-0.22)
Lanier Law Firm Attorneys Earn Spots on 2016 Texas Super Lawyers List
PR Newswire - Wed Sep 07, 10:00AM CDT
The Lanier Law Firm in Houston is home to four attorneys who have earned spots on the 2016 Texas Super Lawyers list for their work in a variety of cases involving everything from maritime law to class actions to appellate work.
JNJ: 119.61 (-0.14)
Johnson & Johnson Partners with Global Citizen to Improve the Trajectory of Human Health Around the World
PR Newswire - Wed Sep 07, 9:25AM CDT
Johnson & Johnson is partnering with social action platform Global Citizen to help give every man, woman and child around the globe the opportunity for a healthier future. The partnership aims to create large-scale change for health systems through integrated solutions to help solve the world's most pressing public health challenges.
JNJ: 119.61 (-0.14)
Post Earnings Coverage as Cooper Cos Earnings Grows 97 Percent
ACCESSWIRE - Wed Sep 07, 8:16AM CDT
LONDON, UK / ACCESSWIRE / September 7, 2016 / Active Wall St. announces its post-earnings coverage on The Cooper Companies Inc. (NYSE: COO). The company released its financial results for the fiscal third quarter 2016 (Q3 FY16) on September 1, 2016. The Contact-lens company updated its financial guidance after stellar earnings results. Register with us now for your free membership at: http://www.activewallst.com/register/.
JNJ: 119.61 (-0.14), VRX: 30.27 (+0.80), COO: 188.56 (+0.26), NVS: 80.36 (+0.21), VRX.TO: 39.05 (+1.19)
AlterG® Announces Appointment of New CEO
PR Newswire - Wed Sep 07, 5:00AM CDT
AlterG, leader in medical and sports technology and emerging in the health and wellness space, today announced the appointment of Mr. Sanjay Gupta as CEO. Mr. Gupta comes to AlterG from healthcare powerhouse Johnson & Johnson, where he held both domestic and international positions with a focused emphasis of serving healthcare professionals and consumers with unique solutions for their unmet needs to create differentiated value related to wellness and disease management.
JNJ: 119.61 (-0.14)
Water Street Appoints Nicklaus Daley to Vice President
PR Newswire - Tue Sep 06, 11:32AM CDT
Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry, announced today that it has appointed Nicklaus Daley to vice president. Mr. Daley augments Water Street's team of senior investment professionals and former executives of health care corporations including Baxter International Inc., CVS Caremark Corporation, Johnson & Johnson and McKesson Corporation.
JNJ: 119.61 (-0.14), BAX: 45.90 (-0.05), CVS: 93.61 (+0.25)
NOVADAQ Announces Appointment of Karen A. Licitra to its Board of Directors
GlobeNewswire - Tue Sep 06, 7:00AM CDT
NOVADAQ Technologies Inc. ("NOVADAQ" or the "Company"
(NASDAQ:NVDQ) (TSX:NDQ), the leading developer and provider of clinically relevant fluorescence imaging solutions for use in surgical and diagnostic procedures, announced today that Karen A. Licitra will be joining the Company's Board of Directors. JNJ: 119.61 (-0.14), NDQ.TO: 16.16 (-0.11), NVDQ: 12.38 (-0.20)
MP Objects Raises $10M Growth Equity From Updata Partners
PR Newswire - Tue Sep 06, 2:30AM CDT
MP Objects BV ("MPO"
, the leading provider of cloud-based Customer Chain Control Software-as-a-Service ("SaaS" , today announced it has raised its first round of outside capital in a $10 million growth equity investment from Updata Partners. MPO's cloud-based SaaS allows its users, including international logistics leaders and blue chip companies such as CEVA, DSV, eBay, Geodis, IBM, Johnson & Johnson, Patagonia and Unilever, to manage and optimize individual customer orders through today's increasingly complex and global supply chains. MPO has experienced very strong revenue growth in recent years, and it will use the new investment to expand into the United States and scale its marketing and sales. JNJ: 119.61 (-0.14), IBM: 161.64 (+1.29)
Johnson & Johnson (JNJ) Approaches New Downside Target of $118.71
Comtex SmarTrend(R) - Thu Sep 01, 9:12AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) have bearishly opened below the pivot of $119.32 today and have reached the first support level of $119.03. Investors may be interested in a cross of the next downside pivot targets of $118.71 and $118.10.
JNJ: 119.61 (-0.14)
Blog Coverage FDA Approves Novartis Erelzi as Biosimilar to Amgen's Enbrel
ACCESSWIRE - Thu Sep 01, 8:15AM CDT
LONDON, UK / ACCESSWIRE / September 1, 2016 / Active Wall St. blog coverage looks at the headline from Novartis AG (NYSE: NVS). On August 30, 2016, the US Food and Drug Administration (FDA) approved Novartis AG's drug Erelzi which is a biosimilar to Amgen Inc.'s (NASDAQ: AMGN) Enbrel. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
JNJ: 119.61 (-0.14), PFE: 34.84 (+0.07), AMGN: 170.63 (-0.21), NVS: 80.36 (+0.21)
GTx Appoints Dr. Garry Neil to Board of Directors
BusinessWire - Thu Sep 01, 6:00AM CDT
GTx, Inc. (Nasdaq: GTXI) today announced that Garry A. Neil, M.D., Chief Scientific Officer, Medgenics, Inc., has been appointed to the GTx, Inc. Board of Directors. Dr. Neil brings significant medical and drug development leadership to the GTx Board of Directors and a proven track record of turning new science into breakthrough commercial products. Dr. Neil will serve on both the Nominating & Governance and Scientific and Development Committees.
GTXI: 0.63 (+0.01), JNJ: 119.61 (-0.14), MDGN: 5.39 (-0.09)
Bendheim Appoints Eric Van de Bovenkamp New Global Sales Manager
PRWeb - Thu Sep 01, 2:36AM CDT
Bendheim, one of the foremost specialty glass companies in the United States, is pleased to welcome Eric Van de Bovenkamp as Global Sales Manager of its Architectural Glass division. Eric will be responsible for supporting and growing the company's extensive sales network throughout North America and overseas.
JNJ: 119.61 (-0.14)
Johnson & Johnson to Participate in 2016 Morgan Stanley Global Health Care Conference
PR Newswire - Wed Aug 31, 9:05AM CDT
Johnson & Johnson (NYSE: JNJ) will participate in the 2016 Morgan Stanley Global Health Care Conference on Wednesday, Sept. 14, at The Grand Hyatt Hotel in New York. Alex Gorsky, Chairman and Chief Executive Officer and Dominic Caruso, Executive Vice President, Chief Financial Officer will represent the Company in a session scheduled at 9:55 a.m. (Eastern Time).
JNJ: 119.61 (-0.14), MS: 31.69 (-0.06)
Multiple Myeloma Market 2030 Forecasts in 2016 Research Report
PR Newswire Europe - Wed Aug 31, 1:01AM CDT
PUNE, Maharashtra, August 31, 2016 /PRNewswire/ --
JNJ: 119.61 (-0.14)
Novartis wins US OK for biosimilar version of Amgen's Enbrel
By LINDA A. JOHNSON and MATTHEW PERRONE - AP - Tue Aug 30, 5:29PM CDT
U.S. regulators on Tuesday approved the first lower-cost version of Enbrel, a blockbuster anti-inflammatory drug from Amgen that is among the top-selling drugs in the world.
JNJ: 119.61 (-0.14), PFE: 34.84 (+0.07), AMGN: 170.63 (-0.21)
Global Contact Lens Market to Rise to 2,135.0 mn Units by 2024; Rising Prevalence of Ophthalmic Disorders and Rising Popularity as Fashion Accessory Boost Global Sales of Contact Lenses - TMR
PR Newswire - Tue Aug 30, 7:30AM CDT
Transparency Market Research estimates that the global contact lens market will expand at a healthy 7.6% CAGR over the period between 2016 and 2024. Expanding at this pace, the market, which had a valuation of US$9.74 bn in 2015 in terms of revenue, is projected to rise to US$18.70 bn by 2024. In terms of volume, the market is expected to rise to 2,135.0 mn units by 2024.
JNJ: 119.61 (-0.14)
Pol Polyprotein Pipeline Review, H1 2016 Featuring GeoVax Labs, Inovio Pharmaceuticals, & Johnson & Johnson - Research and Markets
BusinessWire - Mon Aug 29, 12:13PM CDT
Research and Markets has announced the addition of the "Pol Polyprotein - Pipeline Review, H1 2016" report to their offering.
JNJ: 119.61 (-0.14), INO: 9.05 (+0.05)
EPGL Wins Allowance on First Patent
PR Newswire - Mon Aug 29, 8:00AM CDT
EP Global Communications, Inc. (Public OTC: EPGL) announces today that it has been notified of an allowance from the United States Patent & Trademark Office on its first patent, US 14/668,957 "System for Contact Lens Wireless Communication." With this allowance, EPGL now has several patents pending in the new field of "smart contact lenses" and "augmented vision" technology.
JNJ: 119.61 (-0.14)
Dow 30 Stock Roundup: Pfizer's Big Buy, Boeing's Big Win
Swarup Gupta - Zacks Investment Research - Fri Aug 26, 8:24AM CDT
The Dow suffered losses over the week, weighed down by a number of factors.
MDVN: 80.97 (+0.13), JNJ: 119.61 (-0.14), GE: 31.06 (+0.01), GS: 169.67 (+0.34), PFE: 34.84 (+0.07), AZN: 33.18 (+0.09), MYL: 40.31 (-0.09), BWXT: 39.06 (-0.16), BA: 132.64 (-0.35), VZ: 53.71 (+0.20), MS: 31.69 (-0.06)
Johnson & Johnson to Participate in the 2016 Wells Fargo 11th Annual Healthcare Conference
PR Newswire - Thu Aug 25, 9:00AM CDT
Johnson & Johnson (NYSE: JNJ) will participate in the 2016 Wells Fargo 11th Annual Healthcare Conference on Thursday, Sept. 8, at The Westin Boston Waterfront in Boston, MA. Dominic Caruso, Executive Vice President, Chief Financial Officer will represent the Company in a session scheduled at 10:30 a.m. (Eastern Time).
JNJ: 119.61 (-0.14), WFC: 49.77 (-0.22)
(0)
(0)Scroll down for more posts ▼